Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months

Next Previous
Search
Trial Profile

International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baclofen/naltrexone/sorbitol (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Registrational; Therapeutic Use
  • Acronyms PLEO-CMT
  • Sponsors Pharnext

    • Most Recent Events

    • 16 May 2022 Results presented in a Pharnext Media Release.
    • 19 Oct 2021 According to a Pharnext media release, this trial has been completed with benefits from orphan drug status in Europe and the United States.
    • 28 Apr 2021 According to a Pharnext Media Release, company will host a live conference call and webcast on Thursday April 29th, 2021 to discuss the data.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top